Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
about
A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapyBevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model.Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental GliomaRepurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization
P2860
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
@en
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
@nl
type
label
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
@en
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
@nl
prefLabel
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
@en
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
@nl
P2093
P356
P1476
Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
@en
P2093
Andrew Nash
Keryn A Williams
Pierre Scotney
P304
P356
10.1167/IOVS.15-18239
P407
P50
P577
2016-02-01T00:00:00Z